meningococcal polysaccharide diphtheria toxoid conjugate vaccine

(me-nin-go-kok-al poli-sak-a-ride vax-seen) ,


(trade name),


(trade name)


Therapeutic: vaccines immunizing agents
Pharmacologic: antigens
Pregnancy Category: C


Active immunization to prevent against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.


Induces production of antibodies to several pathologic serogroups of Neisseria meningitidis.

Therapeutic effects

Prevention of invasive meningococcal disease.


Absorption: Well absorbed from IM sites.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: Unknown.

Time/action profile (antibody presence)

IMunknown4 wkunknown


Contraindicated in: Hypersensitivity to meningoccal polysaccharide, diphtheria toxoid or latex; Bleeding disorders (hemophilia, thrombocytopenia, concurrent anticoagulants), unless precautions are taken; Latex allergy (stopper contains latex).
Use Cautiously in: Guillain-Barré syndrome Obstetric: Use only if clearly needed (pregnancy registry participation recommended) use cautiously during lactation; Lactation: Effect on infant unknown; Pediatric: Children <9 mo (safety not established); Geriatric: Safety not established.

Adverse Reactions/Side Effects

Central nervous system

  • irritability (Menveo) (most frequent)
  • fatigue
  • headache
  • malaise
  • syncope (Menveo)


  • diarrhea (Menveo) (most frequent)
  • anorexia
  • vomiting (Menveo)


  • pain at injection site (most frequent)
  • induration
  • redness
  • swelling


  • arthralgia


  • apnea in premature infants (Menveo)


  • anaphylaxis (menveo) (life-threatening)
  • chills
  • Guillain Barre Syndrome


Drug-Drug interaction

Immunosuppressants, antineoplastics, or radiation therapy may ↓ antibody response to and ↑ risk of adverse reactions from vaccines.May ↓ response to pneumococcal vaccine when concurrently administered



Intramuscular (Adults and Children 2–55 yr) 0.5 mL single dose
Intramuscular (Children 9–23 mo) 0.5 mL initially, then 0.5 mL 3 mo later


Intramuscular (Adults and Children 11–55 yr) 0.5 mL single dose
Intramuscular (Children 2–10 yr) 0.5 mL single dose; if patients 2–5 yr are at continued high risk for meningococcal disease, may administer another dose at 2 mo after the first dose
Intramuscular (Children 7–23 mo) 0.5 mL initially, then 0.5 mL in the second yr of life and ≥3 mo after the first dose
Intramuscular (Children 2 mo) 0.5 mL administered at 2, 4, 6, and 12 mo of age


Solution for IM injection: 0.5 mL/vial

Nursing implications

Nursing assessment

  • Review patient's immunization history for contraindications and history of sensitivity to vaccine, a similar vaccine, or latex. Stopper of Menactra vial contains dry natural latex, which may cause allergic reactions in latex-sensitive patients.
  • Monitor patient receiving Menveo for at least 15 min following injection for syncope or allergic reactions.

Potential Nursing Diagnoses

Risk for infection (Indications)


  • Do not confuse Menactra with Menomune (meningococcal polysaccharide vaccine).
  • Record date, lot number, and manufacturer of vaccine as part of immunization record.
  • Intramuscular: Menactra: Administer as a single IM dose, preferrably in deltoid. Do not administer IV, subcutaneously, or intradermally. Inspect solution prior to administration. Do not administer if solution is discolored or contains particulate matter. Do not mix with other vaccines. If administered concurrently with other vaccines, administer a in different sites.
    • Menveo: Combine 2 vials prior to administration. Reconstitute MenA lyophilized conjugate vaccine component with MenCYW-135 liquid conjugate vaccine component by withdrawing entire contents of vial of MenCYW-135 liquid conjugate component and inject into MenA lyophilized conjugate component vial. Invert and shake vial well until the vaccine is dissolved. Withdraw 0.5 mL of reconstituted product; small amount of liquid may remain in vial following withdrawal of dose. Vaccine is clear, colorless, and free from visible foreign particles. Do not administer solutions that are discolored or contain particulate matter. Administer reconstituted vaccine immediately; vaccine is stable at room temperature for up to 8 hours. Inject in anterolateral aspect of thigh in infants or into deltoid muscle in toddlers, adolescents and adults. Do not administer intravenously, subcutaneously or intradermally.

Patient/Family Teaching

  • Inform patient of purpose of vaccine.
  • Advise patient to notify health care professional if pregnancy is planned or suspected or if breast feeding prior to administration. Patients who are pregnant or become aware they were pregnant the time of the immunization, should contact health care professional or Aventis Pasteur Inc. at 1–800–822–2463.

Evaluation/Desired Outcomes

  • Immunity against invasive meningococcal disease.
Drug Guide, © 2015 Farlex and Partners


A quadrivalent conjugate vaccine to prevent invasive meningococcal disease.
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
Vaccines offered are Polio, hepatitis B, Menveo (Meningitis vaccine), DTaP, TD, Tdap, Varicella (chickenpox), MMR, Prevnar (pneumonia), Pediarix (DTaP-HEPB-IPV Combo), Rotarix, hepatitis A, and Gardasil (Human Papillomavirus vaccine).
These vaccines include Prevnar/ Prevnar 13, Gardasil/ Gardasil 9, Vaxigrip, Fluzone, Flublok, Varivax, Proquad, Menactra, Fluarix/ FluLaval, Pneumovax 23, Havrix/ Twinrix/ Engerix-B, Priorix, Priorix Tetra, Varilrix, M-M-R II, Adacel, Boostrix, Menveo, Bexsero, Cervarix, Shingrix, Trumenba, Rotateq, Pentacel, Pentaxim, Imovax, Hexaxim, Zostavax, Rotarix, Sunflorix, Pediarix, Infanrix, Ticovac, Biken Ha, Tetrabik, Mearubik, Varicella (MTP), Jebik V, Flumist/ Fluenz, Bio Thrax, Dukoral, In Live, Ixiaro, HeaLive, In Live, BiLive, EasySix, Imvamune, and Anflu.
Menveo sales declined 15% AER, 12% CER, primarily reflecting supply constraints in Europe and International as well as a strong comparator in 2017 and unfavourable year-on-year CDC stockpile movements in the US, partly offset by demand and share gains in the US.
Menveo sales were down 12% AER, 7% CER, impacted by supply constraints in Europe and International.
Earlier in his career, he served as head of Legal for Novartis Vaccines for North America and Latin America (including for the US launch of Menveo).
* Maintains the use of meningococcal serogroups A, C, W-135, and Y conjugate vaccine (MenACWY) (Menactra, Sanofi Pasteur; Menveo, GlaxoSmithKline) in pregnant women as "Recommended vaccination for adults with an additional risk factor or another indication" (purple).
Two vaccines--for tetanus, diphtheria, and pertussis (Tdap) and meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 (Menveo)--are being studied.
Vaccines sales were up 7% AER, 13% CER, primarily driven by sales of Shingrix in the US as well as increased demand for Bexsero and Hepatitis vaccines, partly offset by declines in Established Vaccines and Menveo. Consumer Healthcare sales declined 3% AER but grew 2% CER reflecting strong performances from power brands in the Pain relief and Oral health categories as well as Cold & flu seasonal brands, partly offset by the adverse comparison with launch sales for Flonase Sensimist in Q1 2017 and the impacts of generic competition to Transderm Scop in the US and the implementation of the Goods & Service Tax in India on 1 July 2017.
Performance was driven by sales of new products including meningitis vaccines Bexsero and Menveo, and there was also strong demand for Fluarix /FluLaval.
Browse Meningococcal Vaccines Market by Meningococcal Combination Vaccines (Bexsero, Trumenba, MenHibrix, Menitorix); Meningococcal Conjugate Vaccines (Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, NmVac4-DT); and Meningococcal Polysaccharide Vaccine (Bi Meningo, Mencevax, Menomune, NmVac4, Quadri Meningo) and Forecast 2017-2021 at
Two meningococcal conjugate vaccines are available in the United States: Menactra, (Sanofi Pasteur), licensed for use in individuals ages 9 months to 55 years; and Menveo (GlaxoSmithKline), licensed for use in individuals ages 2 months to 55 years.
meningitidis bacteria that cause meningococcal disease (A, C, W, and Y): They are the meningococcal polysaccharide vaccine (Menomune) and the meningococcal conjugate vaccine (Menactra and Menveo).